The FDA has granted regular approval selpercatinib (Retevmo®, Eli Lilly and Company) for treatment of adult patients with locally advanced or metastatic rearranged during transfection (RET) gene fusion non-small cell lung cancer (NSCLC). Selpercatinib previously received an accelerated approval from the FDA based on its initial trial results in May 2020. This comes in combination with an FDA approval of the Oncomine Dx Target (ODxT) Test (Thermo Fisher Scientific) as a companion diagnostic for s...

The FDA has granted accelerated approval to selpercatinib (Retevmo®, Eli Lilly and Company) for treatment of adult patients with locally advanced or metastatic rearranged during transfection (RET) gene fusion solid tumors that have progressed on prior systemic therapy, or who have no adequate alternative treatment options. "Selpercatinib, a highly selective RET kinase inhibitor with central nervous system (CNS) activity, was developed specifically to treat patients with RET-altered cancers," wro...

In this interview, Lori Wirth, MD, speaks with i3 Health about selpercatinib (RetevmoTM, Eli Lilly), which was recently approved by the FDA for the treatment of patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), advanced/metastatic RET-mutant medullary thyroid cancer (MTC), and advanced/metastatic RET fusion-positive thyroid cancer. Dr. Wirth, Medical Director of the Center for Head and Neck Cancers at Massachusetts General Hospital and first author of the phase 1/2...

The FDA has approved selpercatinib (RetevmoTM, Eli Lilly), for adult patients with metastatic RET-fusion—positive NSCLC, adult and pediatric patients 12 years of age or older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy, and adult and pediatric patients 12 years of age or older with advanced or metastatic RET-fusion—positive thyroid cancer who require systemic therapy and are refractory to radioactive iodine. Selpercatinib is the first treatm...